An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

What is the purpose of this trial?

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.

Participation Guidelines

Ages: 60 - 85 years

Gender: Both

Janssen Research & Development, LLC

Start Date: 09/25/2017

End Date: 04/01/2023

Last Updated: 02/22/2018

Study HIC#: 1608018299

Get Involved

For more information about this study, contact:
Srinath Ramanan
+1 203-764-8100

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image


Christopher H Van Dyck

Principal Investigator